Long-term efficacy of erenumab in patients with episodic migraine who have failed prior preventive migraine therapies

被引：0
|
作者：
Reuter, U.
Schwedt, T. [1 ]
Kudrow, D. [2 ]
Paemeleire, K.
Zhang, F. [3 ]
Klatt, J.
Picard, H.
Chou, D. [3 ]
Mikol, D. D. [3 ]
机构：
[1] Mayo Clin Arizona, Phoenix, AZ USA
[2] Calif Med Clin Headache, Santa Monica, CA USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO2148
引用
收藏
页码：637 / 637
页数：1
相关论文
共 50 条
  • [21] Conversion from Chronic Migraine (CM) to Episodic Migraine (EM) with long-term erenumab treatment
    Lipton, R. B.
    Tepper, S. J.
    Silberstein, S.
    Kudrow, D.
    Ashina, M.
    Reuter, U.
    Dodick, D.
    Cheng, S.
    Rippon, G. A.
    Zhang, F.
    Mikol, D. D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 636 - 636
  • [22] Conversion from Chronic Migraine (CM) to Episodic Migraine (EM) With Long-Term Erenumab Treatment
    Lipton, Richard
    Tepper, Stewart
    Silberstein, Stephen
    Kudrow, David
    Ashina, Messoud
    Reuter, Uwe
    Dodick, David
    Cheng, Sunfa
    Rippon, Gregory
    Zhang, Feng
    Mikol, Daniel
    NEUROLOGY, 2019, 92 (15)
  • [23] Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication
    Winner, Paul K.
    Singh, Rashmi B. Halker
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [24] Impact of Fremanezumab on Response Rates, Acute Medication Use, and Disability in Patients With Episodic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication
    Winner, Paul
    Singh, Rashmi Halker
    Cohen, Joshua
    Yang, Ronghua
    Yeung, Paul
    Campos, Verena Ramirez
    NEUROLOGY, 2019, 92 (15)
  • [25] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
    Brandes, J.
    Smith, T. R.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 119 - 120
  • [26] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine who have failed at least one prior preventive migraine medication: results of a 1-year study
    Brandes, Jan L.
    Smith, Timothy R.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Carr, Karen
    CEPHALALGIA, 2019, 39 : 233 - 233
  • [27] Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine
    Sakai, Fumihiko
    Takeshima, Takao
    Tatsuoka, Yoshihisa
    Hirata, Koichi
    Cheng, Sunfa
    Numachi, Yotaro
    Peng, Cheng
    Xue, Fei
    Mikol, Daniel D.
    HEADACHE, 2021, 61 (04): : 653 - 661
  • [28] Efficacy of Erenumab For the Treatment of Patients with Episodic Migraine with Aura
    McAllister, Peter
    Pascual Gomez, Julio
    McGill, Lora
    Newman, Lawrence
    Tassorelli, Cristina
    Zhang, Feng
    Picard, Hernan
    Mikol, Daniel
    NEUROLOGY, 2018, 90
  • [29] Efficacy of erenumab for the treatment of patients with episodic migraine with aura
    McAllister, P.
    Pascual, J.
    McGill, L.
    Newman, L.
    Tassorelli, C.
    Zhang, F.
    Picard, H.
    Mikol, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 504 - 504
  • [30] Long-term Efficacy of Erenumab in Chronic Migraine Patients with Acute Medication Overuse
    Tepper, S. J.
    Lipton, R. B.
    Silberstein, S. D.
    Kudrow, D.
    Ashina, M.
    Dodick, D. W.
    Zhang, F.
    Cheng, S.
    Mikol, D. D.
    HEADACHE, 2018, 58 (08): : 1298 - 1300
12345